ACRO Biomedical, which has been valued by the international biomedical community for promoting human tissues and organs engineering and regenerative medicine and the development of biological medical materials, has been officially registered on Taiwan's emerging stock market today(stock code: 6748). 

ACRO Biomedical's core business and future development is in line with the development trend of the precision medicine industry and the needs of tissues and organs regeneration in response to the post-COVID-19 era. There are many symptoms of the coronavirus disease, one of them is pulmonary fibrosis. Human organ regeneration just happens to be one of ACRO Biomedical's important researches. Therefore, it is predicted that ACRO Biomedical will become the most popular investment option in the country following the Coronavirus vaccine stocks.